|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nivolumab (anti-PD- 1; BMS-936558, ONO-4538) and ipilimumab in first-lineNSCLC: Interim phase I results显示文摘 | Antonia SJ Gettinger SN Chow LO~ | 2014 | J Clin Oncol2014，32，5： | 1 |
| 2 | Management of patients with advanced non-small cell lung cancer:current and emerging options显示文摘 | Triano LR Deshpande H Gettinger SN | 2010 | Drugs2010，70，2： | 1 |
| 3 | Novel chemotherapy options for advanced thyroid tumors:small molecules offer great hope显示文摘 | Deshpande HA Gettinger SN Sosa JA | 2008 | Curr Opin Oncol2008，20，1： | 1 |
| 4 | Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previous- ly Treated Advanced Non-Small--Cell Lung Cancer显示文摘 | Gettinger SN Horn L Gandhi L | 2015 | J Clin Oncol2015，33，18： | 1 |
| 5 | Survival and long-term follow-up of the phase I trial of nivolumab (AntiPD-1; BMS- 936558; ONO--4538) in patients (pts) with previously treated ad- vanced non-smallcell lung cancer(NSCLC)显示文摘 | Gettinger SN Horn L Gandhi L | 2013 | J Clin Oncol2013，31，： | 1 |
| 6 | Association of PD--L1 tu- mor expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer (NSCLC) treated with nivolumab(anti- PD- 1 ; BMS- 936558 ;Ono- 4538) 显示文摘 | Antonia SJ Gettinger SN Horn L | 2013 | J Thorac Oncol2013，8，： | 1 |
| 7 | Novel chemotherapy options for advanced thyroid tumors:small molecules offer great hope显示文摘 | Deshpande HA Gettinger SN Sosa JA | 2008 | Curr Opin Oncol2008，20，1： | 1 |
| 8 | Nivolumab (anti-PD-1 ; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC:Interim phase I results显示文摘 | Antonia SJ Gettinger SN Chow LQM | 2014 | J Clin Oncol2014，32，5： | 1 |
| 9 | Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC) 显示文摘 | Antonia SJ Brahmer JR Gettinger SN | 2014 | J Clin Oncol2014，32，5： | 1 |
| 10 | Management of patients with advanced non - small cell lung cancer: current and emerging options显示文摘 | Triano LR Deshpande H Gettinger SN | 2010 | Drugs2010，70，2： | 1 |
| 11 | Clinical activity, safety, and bi- omarkers of MPDL3280A, an engineered PD-LI antibody in pa- tients with loeany advanced or metastatic non-small cell lung cancer (NSCLC) 显示文摘 | SPIGEL DR GETTINGER SN | 2013 | J Clin Oncol2013，31，： | 1 |
| 12 | Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase Ⅲ study (PROFILE 1007) of advanced ALKpositive nonsmall cell lung cancer (NSCLC)显示文摘 | Solomon BJ Gettinger SN Riely GJ | 2013 | J Clin Oncol2013，31，： | 1 |
| 13 | Updated efficacy and safety of the ALK inhibitor AP26113 in patients(pts)with advanced malignancies,including ALK+ non-small cell lung cancer(NSCLC)显示文摘 | Gettinger SN Bazhenova L Salgia R | 2014 | 7 Clin Oncol2014，32，5： | 1 |
| 14 | Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) 显示文摘 | Spigel DR Gettinger SN Horn L | 2013 | J Clin Oncol2013，，： | 1 |
| 15 | Management of patients with advanced non-small cell lung cancer:current and emerging options显示文摘 | Triano LR Deshpande H Gettinger SN | 2010 | Drugs2010，70，2： | 1 |
| 16 | Management of patients with advanced non - small cell lung cancer : current and emerging options 显示文摘 | Triano LR Deshpande H Gettinger SN | 2010 | Drugs2010，70，2： | 1 |
| 17 | ALK inhibitor AP26113 in patients with advanced malignancies, including ALK~ non-small cell lung cancer (NSCLC): updated efficacy and safety data 显示文摘 | Gettinger SN Bazhenova L Salgia R | 2014 | Ann Oncol2014，25，4： | 1 |
| 18 | Overall survival and long-term safety of Nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer显示文摘 | Gettinger SN Horn L Gandhi L | 2015 | J Clin Oncol2015，33，18： | 1 |
| 19 | Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases显示文摘 | Goldberg SB Gettinger SN Mahajan A | 2015 | J Clin Oncol2015，，： | 1 |
| 20 | A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non small cell lung cancer (NSCLC)显示文摘 | Wakelee HA Gettinger SN Engelman JA | 2010 | J Clin Oncol2010，，15： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员